Creatine Kinase (CK) catalyzes the formation of creatinine from creatine phosphate. Elevated serum levels of CK-MB are prime indicators of myocardial cellular injury. It is regarded as a “gold standard” for myocardial infarction diagnosis. The levels of cardiac troponin I (cTnI) or cardiac troponin T also correlate to higher CK-MB) levels. CK-MB levels may also be elevated in chronic renal failure.
Recombinant Human Creatine Kinase MB produced in E.Coli is a single, non-glycosylated, polypeptide chain, having a molecular weight of ~44kDa.
The CKMB is purified by proprietary chromatographic techniques.
The three isoenzymes (MM, MB, and BB) are found in muscle, cardiac and brain tissues. These recombinant proteins are ideal for calibrating diagnostic instruments and researching neuromuscular diseases. Creatine Kinases can be used for indications in many neuromuscular applications. These disorders include cardiac disease, mitochondrial disorders, inflammatory myopathies, myasthenia, polymyositis, McArdle's disease, NMJ disorders, muscular dystrophy, ALS, hypo and hyperthyroid disorders, central core disease, acid maltase deficiency, myoglobinuria, rhabdomyolysis, motor neuron diseases, rheumatic diseases, and other that create elevated or reduced levels of Creatine Kinases.
